Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 7/2009

01.05.2009 | Adis Drug Profile

Aliskiren/Hydrochlorothiazide Combination

In Mild to Moderate Hypertension

verfasst von: Claudine M. Baldwin, Greg L. Plosker

Erschienen in: Drugs | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

  • ▲ Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone.
  • ▲ In double-blind, 8-week clinical trials, aliskiren and HCTZ (as a combination of the individual components or as single-pill combinations) reduced mean sitting systolic and diastolic BP from baseline to a significantly greater extent than placebo, aliskiren monotherapy and HCTZ monotherapy. Aliskiren/HCTZ produced additional BP reductions in patients inadequately responsive to 4 weeks’ prior treatment with aliskiren or HCTZ alone.
  • ▲ Responder rates and BP control rates further demonstrated the benefits of aliskiren/HCTZ combination therapy over monotherapy with individual components in patients with mild to moderate hypertension.
  • ▲ Aliskiren plus HCTZ appeared to be effective as long-term (up to 1 year) combination treatment in an open-label trial.
  • ▲ In a 12-week placebo-controlled trial in obese patients with hypertension, BP reductions and responder and control rates were significantly greater with aliskiren/HCTZ than with HCTZ alone.
  • ▲ Aliskiren/HCTZ was generally well tolerated in clinical trials, with most adverse events being mild and transient in nature.
Literatur
1.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52PubMedCrossRef
2.
Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 Jan; 25(1): 217–26PubMedCrossRef
3.
Nickenig G, Simanenkov V, Lembo G, et al. Efficacy of alis-kiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press 2008; 17 (Suppl. 2): 31–40CrossRef
4.
5.
6.
Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67(12): 1767–92PubMedCrossRef
7.
Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63(19): 2013–26; discussion 2027-8PubMedCrossRef
8.
Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999 May; 57(5): 751–5; discussion 756-8PubMedCrossRef
9.
Croxtall JD, Keating GM. Irbesartan/hydrochlorothiazide in moderate to severe hypertension. Drugs 2008; 68(10): 1465–72PubMedCrossRef
10.
Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1–8PubMedCrossRef
11.
Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126–33PubMedCrossRef
12.
Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12(4): 297–303PubMedCrossRef
13.
Pool J, Gradman A, Kolloch R, et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension [abstract no. 790]. Eur Heart J 2006 Sep; 27 Suppl.: 119. Plus poster presented at the World Congress of Cardiology; 2006 Sep 2–6; Barcelona
14.
Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007 May; 49(5): 1047–55PubMedCrossRef
15.
Ayalasomayajula S, Yeh CM, Vaidyanathan S, et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolar-ization and conduction in healthy subjects. J Clin Pharmacol 2008 Jul; 48(7): 799–811PubMedCrossRef
16.
Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008; 47(8): 515–31PubMedCrossRef
17.
Vaidyanathan S, Limoges D, Yeh C, et al. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers [abstract no. PIII-23]. Clin Pharmacol Ther 2006; 79(2): P64CrossRef
18.
Limoges D, Dieterich HA, Yeh CM, et al. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008 May; 46(5): 252–8PubMed
19.
Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007 Aug; 35(8): 1418–28PubMedCrossRef
20.
Dieterich H, Kemp C, Vaidyanathan S, et al. Pharmacoki-netic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers [abstract no. PI-20]. Clin Pharmacol Ther 2006 Feb; 79(2): 12CrossRef
21.
Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984; 73(3): 359–61PubMedCrossRef
22.
Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007 Mar; 41(3): 456–64PubMedCrossRef
23.
Blumenstein M, Romaszko J, Calderon A, et al. Anti-hypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin 2009; 25(4): 903–10PubMedCrossRef
24.
Gradman AH, Kolloch RE, Meyers M, et al. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension [abstract no. P-384]. J Clin Hypertens (Greenwich) 2007 May; 9 (5 Suppl. A): 160
25.
Calhoun DA, Villamil AS, Chrysant SG, et al. Anti-hypertensive efficacy of aliskiren/hydrochlorothiazide (HCT) combinations in patients with stage 2 hypertension: subgroup analysis of a randomized, double-blind, factorial trial [abstract no. P209]. Hypertension 2008 Oct; 52(4): e97. Plus poster presented at the 62nd Annual High Blood Pressure Conference; 2008 Sep 17; Atlanta (GA)
26.
Prescott MF, Boye SW, Le Breton S, et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension [abstract no. 1014-169]. J Am Coll Cardiol 2007 Mar; 49 (9 Suppl. A): 370. Plus poster presented at the 56th Annual Scientific Session of the American College of Cardiology; 2007 Mar 24; New Orleans (LA)
27.
Metadaten
Titel
Aliskiren/Hydrochlorothiazide Combination
In Mild to Moderate Hypertension
verfasst von
Claudine M. Baldwin
Greg L. Plosker
Publikationsdatum
01.05.2009
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 7/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200969070-00004

Weitere Artikel der Ausgabe 7/2009

Drugs 7/2009 Zur Ausgabe

Review Article

Cranberry and Urinary Tract Infections

Review Article

Ceftaroline

Adis Drug Evaluation

Exemestane

Leading Article

Novel Approaches for Pharmacological Management of Atrial Fibrillation

Adis Drug Evaluation

Bortezomib

Adis Drug Evaluation

Sugammadex